Back to top
more

Merck & Co. (MRK)

(Real Time Quote from BATS)

$106.98 USD

106.98
4,386,467

-1.72 (-1.58%)

Updated Oct 21, 2024 02:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for RYH

Kinjel Shah headshot

What's in Store for These 3 Big Pharma Outperformers in 2022?

by Kinjel Shah

J&J (JNJ), AbbVie (ABBV) and Merck (MRK) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.

Alpine (ALPN) Down on FDA Partial Clinical Hold on Cancer Study

by Zacks Equity Research

The FDA places a partial clinical hold on Alpine's (ALPN) NEON-2 study evaluating the combo of davoceticept plus Merck's Keytruda for treating advanced malignancies. Shares fall.

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE

Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?

by Zacks Equity Research

Sector ETF report for PJP

FDA Nods to Bristol Myers' (BMY) Opdivo for Additional Indication

by Zacks Equity Research

Bristol Myers' (BMY) immuno-oncology Opdivo gets FDA nod for adult patients with resectable non-small cell lung cancer in the neoadjuvant setting in combination with platinum-doublet chemotherapy.

Merck (MRK) Outperforms Industry, What's in Store for 2022?

by Zacks Equity Research

Strong sales of key products like Keytruda and Gardasil, a significant contribution from molnupiravir and positive pipeline/regulatory developments can keep Merck's (MRK) stock afloat in 2022.

Merck (MRK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Merck (MRK) closed at $77.83 in the latest trading session, marking a +0.88% move from the prior day.

Ekta Bagri headshot

WHO Recommends Merck (MRK) Oral Pill for Certain COVID Patients

by Ekta Bagri

Merck's (MRK) and Ridgeback Biotherapeutics' oral antiviral drug molnupiravir has been included in the treatment guidelines for COVID-19 by WHO.

Nektar (NKTR) Q4 Earnings Top, Three Bempeg Filings Due in 2022

by Zacks Equity Research

Nektar (NKTR) reports mixed fourth-quarter 2021 results. The company remains on track to report top-line data from three registrational studies on bempegaldesleukin in the first half of 2022.

Mirati (MRTX) Q4 Earnings and Sales Fall Short of Estimates

by Zacks Equity Research

Mirati Therapeutics (MRTX) reports wider-than-expected fourth-quarter loss. Sales miss estimates.

Iovance (IOVA) Announces Wider-Than-Anticipated Q4 Loss

by Zacks Equity Research

Iovance Biotherapeutics' (IOVA) fourth-quarter loss is wider than expected. The company is on track to file regulatory submission for lifileucel in melanoma by first-half 2022.

Moderna (MRNA) Q4 Earnings Top, COVID-19 Vaccine Brings $7B

by Zacks Equity Research

Moderna's (MRNA) COVID-19 vaccine sales beat expectations. The company delivers 297 million doses of its COVID-19 vaccine during the fourth quarter. Stock gains in pre-market.

The Zacks Analyst Blog Highlights Merck & Co, Shopify, Intercontinental Exchange, Barrick Gold Corp and NXP Semiconductors

by Zacks Equity Research

Merck & Co, Shopify, Intercontinental Exchange, Barrick Gold Corp and NXP Semiconductors are included in this analyst blog.

AstraZeneca (AZN) Enhertu Effective in HER2-Low Breast Cancer

by Zacks Equity Research

AstraZeneca's (AZN) DESTINY-Breast04 is the first-ever phase III study of a HER2-directed therapy to show a statistically significant and clinically meaningful survival benefit in patients with HER2-low metastatic breast cancer.

Is a Beat Likely for Moderna (MRNA) This Earnings Season?

by Zacks Equity Research

Investor focus is likely to be on the progress of Moderna's (MRNA) late-stage pipeline candidates on the fourth-quarter earnings call that reduce its dependence on Spikevax.

    Mark Vickery headshot

    Top Research Reports for Merck, Shopify & Intercontinental Exchange

    by Mark Vickery

    Today's Research Daily features new research reports on 16 major stocks, including Merck & Co., Inc. (MRK), Shopify Inc. (SHOP), and Intercontinental Exchange, Inc. (ICE).

    Exelixis (EXEL) Q4 Earnings & Revenues Beat, Cabometyx Strong

    by Zacks Equity Research

    Exelixis (EXEL) beats on both earnings and revenues in the fourth quarter. Both figures increase on a year-over-year basis.

    Mirati (MRTX) Down on Longer Review Period for Adagrasib NDA

    by Zacks Equity Research

    The FDA accepts Mirati's (MRTX) NDA for its lung cancer candidate, adagrasib. A decision is expected by Dec 14, 2022.

    Alkermes' (ALKS) Q4 Earnings and Revenues Beat Estimates

    by Zacks Equity Research

    Alkermes (ALKS) rides high on both earnings and sales beating estimates in the fourth quarter of 2021.

    Is Invesco Defensive Equity ETF (DEF) a Strong ETF Right Now?

    by Zacks Equity Research

    Smart Beta ETF report for DEF

    Is Merck & Co. (MRK) Suitable for Value Investors Now?

    by Zacks Equity Research

    Let's see if Merck & Co. (MRK) stock is a good choice for value-oriented investors right now from multiple angles.

    Corcept's (CORT) Q4 Earnings Beat Estimates, Revenues Miss

    by Zacks Equity Research

    Corcept's (CORT) earnings beat estimates in the fourth quarter of 2021 while revenues miss the same.

    Is Hartford Multifactor Developed Markets exUS ETF (RODM) a Strong ETF Right Now?

    by Zacks Equity Research

    Smart Beta ETF report for RODM

    Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?

    by Zacks Equity Research

    Style Box ETF report for DEF